Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 179

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

RAS-mediated oncogenic signaling pathways in human malignancies

Khan, Abdul Q., Kuttikrishnan, Shilpa, Siveen, Kodappully S., Prabhu, Kirti S., Shanmugakonar, Muralitharan, Al- Naemi, Hamda A., Haris, Mohammad, Dermime, Said, Uddin, Shahab · 2019 · Seminars in Cancer Biology

Abstract

Abnormally activated RAS proteins are the main oncogenic driver that governs the functioning of major signaling pathways involved in the initiation and development of human malignancies. Mutations in RAS genes and or its regulators, most frequent in human cancers, are the main force for incessant RAS activation and associated pathological conditions including cancer. In general, RAS is the main upstream regulator of the highly conserved signaling mechanisms associated with a plethora of important cellular activities vital for normal homeostasis. Mutated or the oncogenic RAS aberrantly activates a web of interconnected signaling pathways including RAF-MEK (mitogen-activated protein kinase kinase)-ERK (extracellular signal-regulated kinase), phosphoinositide-3 kinase (PI3K)/AKT (protein kinase B), protein kinase C (PKC) and ral guanine nucleotide dissociation stimulator (RALGDS), etc., leading to uncontrolled transcriptional expression and reprogramming in the functioning of a range of nuclear and cytosolic effectors critically associated with the hallmarks of carcinogenesis. This review highlights the recent literature on how oncogenic RAS negatively use its signaling web in deregulating the expression and functioning of various effector molecules in the pathogenesis of human malignancies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.semcancer.2018.03.001

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 30 references

Research works printed but not linked: 204

  1. Rojas, 2012, The Ras protein superfamily: evolutionary tree and role of conserved amino acids, J. Cell Biol., 196, 189, 10.1083/jcb.201103008 · DOI · Paper page
  2. Wennerberg, 2005, The Ras superfamily at a glance, J. Cell Sci., 118, 843, 10.1242/jcs.01660 · DOI · Paper page
  3. Ward, 2012, Targeting oncogenic Ras signaling in hematologic malignancies, Blood, 120, 3397, 10.1182/blood-2012-05-378596 · DOI · Paper page
  4. Vigil, 2010, Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy, Nat. Rev. Cancer, 10, 842, 10.1038/nrc2960 · DOI · Paper page
  5. Mann, 2016, KRAS-related proteins in pancreatic cancer, Pharmacol. Ther., 168, 29, 10.1016/j.pharmthera.2016.09.003 · DOI · Paper page
  6. LeBleu, 2013, Origin and function of myofibroblasts in kidney fibrosis, Nat. Med., 19, 1047, 10.1038/nm.3218 · DOI · Paper page
  7. Logsdon, 2016, The significance of Ras activity in pancreatic cancer initiation, Int. J. Biol. Sci., 12, 338, 10.7150/ijbs.15020 · DOI
  8. Baines, 2011, Inhibition of Ras for cancer treatment: the search continues, Future Med. Chem., 3, 1787, 10.4155/fmc.11.121 · DOI · Paper page
  9. Rodenhuis, 1992, Ras and human tumors, Semin. Cancer Biol., 3, 241
  10. Mengoli, 2016, K-RAS mutations indicating primary resistance to crizotinib in ALK-rearranged adenocarcinomas of the lung: report of two cases and review of the literature, Lung Cancer, 93, 55, 10.1016/j.lungcan.2016.01.002 · DOI
  11. Beaupre, 1999, RAS and leukemia: from basic mechanisms to gene-directed therapy, J. Clin. Oncol., 17, 1071, 10.1200/JCO.1999.17.3.1071 · DOI · Paper page
  12. Bahrami, 2018, The therapeutic potential of targeting the BRAF mutation in patients with colorectal cancer, J. Cell. Physiol., 233, 2162, 10.1002/jcp.25952 · DOI
  13. Martinelli, 2017, Cancer resistance to therapies against the EGFR-RAS-RAF pathway: the role of MEK, Cancer Treat. Rev., 53, 61, 10.1016/j.ctrv.2016.12.001 · DOI
  14. Coelho, 2017, Oncogenic RAS signaling promotes tumor immunoresistance by stabilizing PD-L1 mRNA, Immunity, 47, 1083, 10.1016/j.immuni.2017.11.016 · DOI · Paper page
  15. Chin, 1999, Essential role for oncogenic Ras in tumour maintenance, Nature, 400, 468, 10.1038/22788 · DOI · Paper page
  16. Knickelbein, 2015, Mutant KRAS as a critical determinant of the therapeutic response of colorectal cancer, Genes Dis., 2, 4, 10.1016/j.gendis.2014.10.002 · DOI
  17. Barbacid, 1987, Ras genes, Annu. Rev. Biochem, 56, 779, 10.1146/annurev.bi.56.070187.004023 · DOI · Paper page
  18. Cohen, 1989, Expression of the H-ras proto-oncogene is controlled by alternative splicing, Cell, 58, 461, 10.1016/0092-8674(89)90427-3 · DOI
  19. Seeburg, 1984, Biological properties of human c-Ha-ras1 genes mutated at codon 12, Nature, 312, 71, 10.1038/312071a0 · DOI · Paper page
  20. Bos, 1989, Ras oncogenes in human cancer: a review, Cancer Res., 49, 4682
  21. Parsons, 2002, Occurrence of H-ras codon 61 CAA to AAA mutation during mouse liver tumor progression, Carcinogenesis, 23, 943, 10.1093/carcin/23.6.943 · doi:10.1093/carcin/23.6.943
  22. Smith, 2010, Activating K-Ras mutations outwith ‘hotspot’ codons in sporadic colorectal tumours–implications for personalised cancer medicine, Br. J. Cancer, 102, 693, 10.1038/sj.bjc.6605534 · DOI · Paper page
  23. Johnson, 2001, Somatic activation of the K-ras oncogene causes early onset lung cancer in mice, Nature, 410, 1111, 10.1038/35074129 · DOI · Paper page
  24. Stolze, 2015, Comparative analysis of KRAS codon 12, 13, 18, 61, and 117 mutations using human MCF10A isogenic cell lines, Sci. Rep., 5, 8535, 10.1038/srep08535 · DOI
  25. Phipps, 2013, KRAS-mutation status in relation to colorectal cancer survival: the joint impact of correlated tumour markers, Br. J. Cancer, 108, 1757, 10.1038/bjc.2013.118 · DOI · Paper page
  26. Imamura, 2012, Specific mutations in KRAS codons 12 and 13, and patient prognosis in 1075 BRAF wild-type colorectal cancers, Clin. Cancer Res., 18, 4753, 10.1158/1078-0432.CCR-11-3210 · DOI · Paper page
  27. Edkins, 2006, Recurrent KRAS codon 146 mutations in human colorectal cancer, Cancer Biol. Ther., 5, 928, 10.4161/cbt.5.8.3251 · DOI · Paper page
  28. Omholt, 2002, Screening of N-ras codon 61 mutations in paired primary and metastatic cutaneous melanomas: mutations occur early and persist throughout tumor progression, Clin. Cancer Res., 8, 3468
  29. Irahara, 2010, NRAS mutations are rare in colorectal cancer, Diagn. Mol. Pathol., 19, 157, 10.1097/PDM.0b013e3181c93fd1 · DOI · Paper page
  30. Matsumoto, 1997, Novel small GTPase M-Ras participates in reorganization of actin cytoskeleton, Oncogene, 15, 2409, 10.1038/sj.onc.1201416 · DOI
  31. Huff, 1997, R-Ras is regulated by activators and effectors distinct from those that control Ras function, Oncogene, 14, 133, 10.1038/sj.onc.1200815 · DOI
  32. Fernandez-Medarde, 2011, Ras in cancer and developmental diseases, Genes Cancer, 2, 344, 10.1177/1947601911411084 · DOI · Paper page
  33. Caldas, 1994, Detection of K-ras mutations in the stool of patients with pancreatic adenocarcinoma and pancreatic ductal hyperplasia, Cancer Res., 54, 3568
  34. Lu, 2017, Evaluation of K-ras and p53 expression in pancreatic adenocarcinoma using the cancer genome atlas, PLoS One, 12, e0181532, 10.1371/journal.pone.0181532 · DOI
  35. Lee, 2016, KRAS, GNAS, and RNF43 mutations in intraductal papillary mucinous neoplasm of the pancreas: a meta-analysis, SpringerPlus, 5, 1172, 10.1186/s40064-016-2847-4 · DOI
  36. Hashimoto, 2016, Heterogeneity of KRAS mutations in pancreatic ductal adenocarcinoma, Pancreas, 45, 1111, 10.1097/MPA.0000000000000624 · DOI
  37. Miglio, 2014, KRAS mutational analysis in ductal adenocarcinoma of the pancreas and its clinical significance, Pathol. Res. Pract., 210, 307, 10.1016/j.prp.2014.01.011 · DOI
  38. Sinn, 2014, KRAS mutations in codon 12 or 13 are associated with worse prognosis in pancreatic ductal adenocarcinoma, Pancreas, 43, 578, 10.1097/MPA.0000000000000077 · DOI
  39. Immervoll, 2006, Molecular analysis of the EGFR-RAS-RAF pathway in pancreatic ductal adenocarcinomas: lack of mutations in the BRAF and EGFR genes, Virchows Arch., 448, 788, 10.1007/s00428-006-0191-8 · DOI
  40. Kawesha, 2000, K-ras oncogene subtype mutations are associated with survival but not expression of p53, p16(INK4A), p21(WAF-1), cyclin D1, erbB-2 and erbB-3 in resected pancreatic ductal adenocarcinoma, Int. J. Cancer, 89, 469, 10.1002/1097-0215(20001120)89:6<469::AID-IJC1>3.0.CO;2-L · DOI
  41. Whyte, 1997, K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors, J. Biol. Chem., 272, 14459, 10.1074/jbc.272.22.14459 · DOI · Paper page
  42. Weden, 2011, Long-term follow-up of patients with resected pancreatic cancer following vaccination against mutant K-ras, Int. J. Cancer, 128, 1120, 10.1002/ijc.25449 · DOI · Paper page
  43. Poulin, 2017, No back seat for a progression event-K-RAS as a therapeutic target in CRC, Genes Dev., 31, 333, 10.1101/gad.297630.117 · DOI
  44. Abubaker, 2009, Prognostic significance of alterations in KRAS isoforms KRAS-4A/4B and KRAS mutations in colorectal carcinoma, J. Pathol., 219, 435, 10.1002/path.2625 · DOI
  45. Lievre, 2018, RAS mutation testing in patients with metastatic colorectal cancer in French clinical practice: a status report in 2014, Dig. Liver Dis., 10.1016/j.dld.2017.12.029 · DOI
  46. Petaccia de Macedo, 2017, KRAS mutation status is highly homogeneous between areas of the primary tumor and the corresponding metastasis of colorectal adenocarcinomas: one less problem in patient care, Am. J. Cancer. Res., 7, 1978
  47. Zekri, 2017, Mutations in codons 12 and 13 of K-ras exon 2 in colorectal tumors of Saudi Arabian patients: frequency, clincopathological associations, and clinical outcomes, Genet. Mol. Res., 16, 10.4238/gmr16019369 · DOI
  48. Kafatos, 2017, RAS mutation prevalence among patients with metastatic colorectal cancer: a meta-analysis of real-world data, Biomark. Med., 10.2217/bmm-2016-0358 · DOI
  49. Vogelstein, 1988, Genetic alterations during colorectal-tumor development, N. Engl. J. Med., 319, 525, 10.1056/NEJM198809013190901 · DOI · Paper page
  50. Chang, 2016, Mutation spectra of RAS gene family in colorectal cancer, Am. J. Surg., 212, 537, 10.1016/j.amjsurg.2016.02.013 · DOI
  51. Conlin, 2005, The prognostic significance of K-ras, p53, and APC mutations in colorectal carcinoma, Gut, 54, 1283, 10.1136/gut.2005.066514 · DOI · Paper page
  52. Dinu, 2014, Prognostic significance of KRAS gene mutations in colorectal cancer–preliminary study, J. Med. Life, 7, 581
  53. Lohinai, 2017, KRAS-mutation incidence and prognostic value are metastatic site-specific in lung adenocarcinoma: poor prognosis in patients with KRAS mutation and bone metastasis, Sci. Rep., 7, 39721, 10.1038/srep39721 · DOI
  54. Cejas, 2009, KRAS mutations in primary colorectal cancer tumors and related metastases: a potential role in prediction of lung metastasis, PLoS One, 4, e8199, 10.1371/journal.pone.0008199 · DOI
  55. Lievre, 2008, KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab, J. Clin. Oncol., 26, 374, 10.1200/JCO.2007.12.5906 · DOI · Paper page
  56. Raponi, 2008, KRAS mutations predict response to EGFR inhibitors, Curr. Opin. Pharmacol., 8, 413, 10.1016/j.coph.2008.06.006 · DOI
  57. Saif, 2009, Randomized double-blind phase II trial comparing gemcitabine plus LY293111 versus gemcitabine plus placebo in advanced adenocarcinoma of the pancreas, Cancer J., 15, 339, 10.1097/PPO.0b013e3181b36264 · DOI
  58. Howell, 2013, RAS mutations in thyroid cancer, Oncologist, 18, 926, 10.1634/theoncologist.2013-0072 · DOI · Paper page
  59. Bhaijee, 2011, Molecular analysis of thyroid tumors, Endocr. Pathol., 22, 126, 10.1007/s12022-011-9170-y · DOI
  60. Abubaker, 2008, Clinicopathological analysis of papillary thyroid cancer with PIK3CA alterations in a Middle Eastern population, J. Clin. Endocrinol. Metab., 93, 611, 10.1210/jc.2007-1717 · DOI · Paper page
  61. Latteyer, 2016, Targeted next-generation sequencing for TP53, RAS, BRAF, ALK and NF1 mutations in anaplastic thyroid cancer, Endocrine, 54, 733, 10.1007/s12020-016-1080-9 · doi:10.1007/s12020-016-1080-9
  62. Duman, 2014, Evaluation of PTEN, PI3K, MTOR, and KRAS expression and their clinical and prognostic relevance to differentiated thyroid carcinoma, Contemp. Oncol. (Pozn.), 18, 234
  63. Fakhruddin, 2017, BRAF and NRAS mutations in papillary thyroid carcinoma and concordance in BRAF mutations between primary and corresponding lymph node metastases, Sci. Rep., 7, 4666, 10.1038/s41598-017-04948-3 · doi:10.1038/s41598-017-04948-3
  64. Wells, 2009, Targeting the RET pathway in thyroid cancer, Clin. Cancer Res., 15, 7119, 10.1158/1078-0432.CCR-08-2742 · DOI · Paper page
  65. Lee, 2010, Complications of radioactive iodine treatment of thyroid carcinoma, J. Natl. Compr. Cancer Netw., 8, 1277, 10.6004/jnccn.2010.0094 · DOI
  66. Hong, 2009, Phase I trial of a combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in advanced malignancies, Clin. Cancer Res., 15, 7061, 10.1158/1078-0432.CCR-09-1241 · DOI
  67. Reuter, 2000, Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies, Blood, 96, 1655, 10.1182/blood.V96.5.1655 · DOI · Paper page
  68. Wang, 2010, Endogenous oncogenic Nras mutation promotes aberrant GM-CSF signaling in granulocytic/monocytic precursors in a murine model of chronic myelomonocytic leukemia, Blood, 116, 5991, 10.1182/blood-2010-04-281527 · DOI
  69. Zhou, 2017, KRAS overexpression independent of RAS mutations confers an adverse prognosis in cytogenetically normal acute myeloid leukemia, Oncotarget, 8, 66087, 10.18632/oncotarget.19798 · DOI
  70. Liang, 2018, Mutational status of NRAS, KRAS, and PTPN 11 genes is associated with genetic/cytogenetic features in children with B-precursor acute lymphoblastic leukemia, Pediatr. Blood Cancer, 65, 10.1002/pbc.26786 · DOI
  71. De Melo, 1997, N-ras gene point mutations in Brazilian acute myelogenous leukemia patients correlate with a poor prognosis, Leuk. Lymphoma, 24, 309, 10.3109/10428199709039018 · DOI
  72. Kiyoi, 1999, Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia, Blood, 93, 3074
  73. Shih, 2004, Acquisition of FLT3 or N-ras mutations is frequently associated with progression of myelodysplastic syndrome to acute myeloid leukemia, Leukemia, 18, 466, 10.1038/sj.leu.2403274 · DOI
  74. Lubbert, 1990, N-ras gene point mutations in childhood acute lymphocytic leukemia correlate with a poor prognosis, Blood, 75, 1163, 10.1182/blood.V75.5.1163.1163 · DOI
  75. Paquette, 1993, N-ras mutations are associated with poor prognosis and increased risk of leukemia in myelodysplastic syndrome, Blood, 82, 590, 10.1182/blood.V82.2.590.590 · DOI · Paper page
  76. Marin, 2010, Current status of imatinib as frontline therapy for chronic myeloid leukemia, Semin. Hematol., 47, 312, 10.1053/j.seminhematol.2010.06.003 · DOI
  77. Timar, 2014, The clinical relevance of KRAS gene mutation in non-small-cell lung cancer, Curr. Opin. Oncol., 26, 138, 10.1097/CCO.0000000000000051 · DOI
  78. Suzuki, 1990, Detection of ras gene mutations in human lung cancers by single-strand conformation polymorphism analysis of polymerase chain reaction products, Oncogene, 5, 1037
  79. Marabese, 2015, KRAS mutations affect prognosis of non-small-cell lung cancer patients treated with first-line platinum containing chemotherapy, Oncotarget, 6, 34014, 10.18632/oncotarget.5607 · DOI
  80. Forest, 2017, EGFR, KRAS, BRAF and HER2 testing in metastatic lung adenocarcinoma: value of testing on samples with poor specimen adequacy and analysis of discrepancies, Exp. Mol. Pathol., 103, 306, 10.1016/j.yexmp.2017.11.013 · DOI
  81. Jia, 2017, Characterization of distinct types of KRAS mutation and its impact on first-line platinum-based chemotherapy in Chinese patients with advanced non-small cell lung cancer, Oncol. Lett., 14, 6525
  82. Turhal, 2015, Prevalence of K-Ras mutations in hepatocellular carcinoma: a Turkish Oncology Group pilot study, Mol. Clin. Oncol., 3, 1275, 10.3892/mco.2015.633 · DOI
  83. Ye, 2014, Synergistic function of Kras mutation and HBx in initiation and progression of hepatocellular carcinoma in mice, Oncogene, 33, 5133, 10.1038/onc.2013.468 · DOI
  84. Hou, 2014, Mutation analysis of key genes in RAS/RAF and PI3K/PTEN pathways in Chinese patients with hepatocellular carcinoma, Oncol. Lett., 8, 1249, 10.3892/ol.2014.2253 · DOI
  85. Tilch, 2014, Mutations in EGFR, BRAF and RAS are rare in triple-negative and basal-like breast cancers from Caucasian women, Breast Cancer Res. Treat., 143, 385, 10.1007/s10549-013-2798-1 · DOI
  86. Cejalvo, 2016, Clinical implications of routine genomic mutation sequencing in PIK3CA/AKT1 and KRAS/NRAS/BRAF in metastatic breast cancer, Breast Cancer Res. Treat., 160, 69, 10.1007/s10549-016-3980-z · DOI
  87. Wang, 2015, Study of PIK3CA, BRAF, and KRAS mutations in breast carcinomas among Chinese women in Qinghai, Genet. Mol. Res., 14, 14840, 10.4238/2015.November.18.49 · DOI
  88. Uvirova, 2015, Comparison of the prevalence of KRAS-LCS6 polymorphism (rs61764370) within different tumour types (colorectal, breast, non-small cell lung cancer and brain tumours). A study of the Czech population, Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub., 159, 466, 10.5507/bp.2015.029 · doi:10.5507/bp.2015.029
  89. Xing, 2017, Mutation of NRAS is a rare genetic event in ovarian low-grade serous carcinoma, Hum. Pathol., 68, 87, 10.1016/j.humpath.2017.08.021 · doi:10.1016/j.humpath.2017.08.021
  90. Zannoni, 2016, Molecular status of PI3KCA, KRAS and BRAF in ovarian clear cell carcinoma: an analysis of 63 patients, J. Clin. Pathol., 69, 1088, 10.1136/jclinpath-2016-203776 · DOI
  91. Nanus, 1990, Infrequent ras oncogene point mutations in renal cell carcinoma, J. Urol., 143, 175, 10.1016/S0022-5347(17)39905-6 · DOI
  92. Ponti, 2017, BRAF, NRAS and C-KIT advanced melanoma: clinico-pathological features, targeted-therapy strategies and survival, Anticancer Res., 37, 7043
  93. Munoz-Couselo, 2017, NRAS-mutant melanoma: current challenges and future prospect, Onco Targets Ther., 10, 3941, 10.2147/OTT.S117121 · DOI · Paper page
  94. Queirolo, 2017, Binimetinib for the treatment of NRAS-mutant melanoma, Expert Rev. Anticancer Ther., 17, 985, 10.1080/14737140.2017.1374177 · DOI
  95. Heppt, 2017, Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care, BMC Cancer, 17, 536, 10.1186/s12885-017-3529-5 · DOI
  96. McDaniel, 2014, HRAS mutations are frequent in inverted urothelial neoplasms, Hum. Pathol., 45, 1957, 10.1016/j.humpath.2014.06.003 · DOI
  97. Beukers, 2014, HRAS mutations in bladder cancer at an early age and the possible association with the Costello Syndrome, Eur. J. Hum. Genet., 22, 837, 10.1038/ejhg.2013.251 · doi:10.1038/ejhg.2013.251
  98. Wang, 2012, H-ras mutation detection in bladder cancer by COLD-PCR analysis and direct sequencing, Urol. Int., 88, 350, 10.1159/000336132 · DOI
  99. Jinesh, 2017, Molecular genetics and cellular events of K-Ras-driven tumorigenesis, Oncogene
  100. Fey, 2016, The complexities and versatility of the RAS-to-ERK signalling system in normal and cancer cells, Semin. Cell Dev. Biol., 58, 96, 10.1016/j.semcdb.2016.06.011 · DOI
  101. Yang, 2017, Targeting the Ras/Raf/MEK/ERK pathway in hepatocellular carcinoma, Oncol. Lett., 13, 1041, 10.3892/ol.2017.5557 · DOI · Paper page
  102. Cseh, 2014, “RAF” neighborhood: protein-protein interaction in the Raf/Mek/Erk pathway, FEBS Lett., 588, 2398, 10.1016/j.febslet.2014.06.025 · DOI
  103. Imperial, 2017, Comprehensive pancancer genomic analysis reveals (RTK)-RAS-RAF-MEK as a key dysregulated pathway in cancer: its clinical implications, Semin. Cancer Biol.
  104. Dorard, 2017, Deciphering the RAS/ERK pathway in vivo, Biochem. Soc. Trans., 45, 27, 10.1042/BST20160135 · DOI
  105. Sriskanthadevan-Pirahas, 2018, Ras/ERK-signalling promotes tRNA synthesis and growth via the RNA polymerase III repressor Maf1 in Drosophila, PLoS Genet., 14, e1007202, 10.1371/journal.pgen.1007202 · DOI
  106. Downward, 2003, Targeting RAS signalling pathways in cancer therapy, Nat. Rev. Cancer, 3, 11, 10.1038/nrc969 · DOI · Paper page
  107. Sheridan, 2013, Inhibiting the RAS-PI3K pathway in cancer therapy, Enzymes, 34, 107, 10.1016/B978-0-12-420146-0.00005-6 · DOI
  108. Jankovic, 1996, International conference on chronic myelocytic leukemia: biology and treatment organised by the Scientific Committee of The Israel Society of Hematology, Jerusalem, Israel, 28-31 January 1996, Leukemia, 10, 1667
  109. Li, 2017, R-Ras-Akt axis induces endothelial lumenogenesis and regulates the patency of regenerating vasculature, Nat. Commun., 8, 1720, 10.1038/s41467-017-01865-x · DOI
  110. Gagliardi, 2017, PDK1: at the crossroad of cancer signaling pathways, Semin. Cancer Biol.
  111. Martini, 2014, PI3K/AKT signaling pathway and cancer: an updated review, Ann. Med., 46, 372, 10.3109/07853890.2014.912836 · DOI · Paper page
  112. Guin, 2015, The RAS-RAL axis in cancer: evidence for mutation-specific selectivity in non-small cell lung cancer, Acta Pharmacol. Sin., 36, 291, 10.1038/aps.2014.129 · DOI
  113. Suryaraja, 2013, The E3 ubiquitin ligase Itch regulates tumor suppressor protein RASSF5/NORE1 stability in an acetylation-dependent manner, Cell Death Dis., 4, e565, 10.1038/cddis.2013.91 · DOI
  114. Bee, 2010, Growth and tumor suppressor NORE1A is a regulatory node between Ras signaling and microtubule nucleation, J. Biol. Chem., 285, 16258, 10.1074/jbc.M109.081562 · DOI
  115. Calvisi, 2009, NORE1A tumor suppressor candidate modulates p21CIP1 via p53, Cancer Res., 69, 4629, 10.1158/0008-5472.CAN-08-3672 · DOI
  116. Stacey, 1984, Transformation of NIH 3T3 cells by microinjection of Ha-ras p21 protein, Nature, 310, 508, 10.1038/310508a0 · DOI · Paper page
  117. McCarthy, 1995, Rapid induction of heparin-binding epidermal growth factor/diphtheria toxin receptor expression by Raf and Ras oncogenes, Genes Dev., 9, 1953, 10.1101/gad.9.16.1953 · DOI · Paper page
  118. Woods, 2001, Induction of beta3-integrin gene expression by sustained activation of the Ras-regulated Raf-MEK-extracellular signal-regulated kinase signaling pathway, Mol. Cell. Biol., 21, 3192, 10.1128/MCB.21.9.3192-3205.2001 · DOI
  119. Dajee, 2002, Epidermal Ras blockade demonstrates spatially localized Ras promotion of proliferation and inhibition of differentiation, Oncogene, 21, 1527, 10.1038/sj.onc.1205287 · DOI
  120. Amin, 2015, Evasion of anti-growth signaling: a key step in tumorigenesis and potential target for treatment and prophylaxis by natural compounds, Semin. Cancer Biol., 35, S55, 10.1016/j.semcancer.2015.02.005 · DOI
  121. Chen, 2001, Regulation of glut1 mRNA by hypoxia-inducible factor-1: interaction between H-ras and hypoxia, J. Biol. Chem., 276, 9519, 10.1074/jbc.M010144200 · DOI · Paper page
  122. Blum, 2005, Ras inhibition in glioblastoma down-regulates hypoxia-inducible factor-1alpha, causing glycolysis shutdown and cell death, Cancer Res., 65, 999, 10.1158/0008-5472.999.65.3 · DOI · Paper page
  123. Semenza, 2007, Hypoxia and cancer, Cancer Metastasis Rev., 26, 223, 10.1007/s10555-007-9058-y · DOI · Paper page
  124. Flier, 1987, Elevated levels of glucose transport and transporter messenger RNA are induced by ras or src oncogenes, Science, 235, 1492, 10.1126/science.3103217 · DOI · Paper page
  125. Shaw, 2006, Glucose metabolism and cancer, Curr. Opin. Cell Biol., 18, 598, 10.1016/j.ceb.2006.10.005 · DOI · Paper page
  126. Lock, 2011, Autophagy facilitates glycolysis during Ras-mediated oncogenic transformation, Mol. Biol. Cell, 22, 165, 10.1091/mbc.e10-06-0500 · DOI · Paper page
  127. Kim, 2011, Involvement of autophagy in oncogenic K-Ras-induced malignant cell transformation, J. Biol. Chem., 286, 12924, 10.1074/jbc.M110.138958 · DOI · Paper page
  128. Rak, 2004, Oncogenes and tumor angiogenesis: the question of vascular supply and vascular demand, Semin. Cancer Biol., 14, 93, 10.1016/j.semcancer.2003.09.014 · DOI
  129. Rak, 1995, Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis, Cancer Res., 55, 4575
  130. Kranenburg, 2004, Stimulation of angiogenesis by Ras proteins, Biochim. Biophys. Acta, 1654, 23
  131. Giehl, 2005, Oncogenic Ras in tumour progression and metastasis, Biol. Chem., 386, 193, 10.1515/BC.2005.025 · DOI · Paper page
  132. Campbell, 2004, Oncogenic Ras and its role in tumor cell invasion and metastasis, Semin. Cancer Biol., 14, 105, 10.1016/j.semcancer.2003.09.015 · DOI · Paper page
  133. Nebert, 2002, Transcription factors and cancer: an overview, Toxicology, 181–182, 131, 10.1016/S0300-483X(02)00269-X · DOI
  134. Lee, 2013, Transcriptional regulation and its misregulation in disease, Cell, 152, 1237, 10.1016/j.cell.2013.02.014 · DOI · Paper page
  135. Dolcet, 2005, NF-kB in development and progression of human cancer, Virchows Arch., 446, 475, 10.1007/s00428-005-1264-9 · DOI · Paper page
  136. Tilborghs, 2017, The role of Nuclear Factor-kappa B signaling in human cervical cancer, Crit. Rev. Oncol. Hematol., 120, 141, 10.1016/j.critrevonc.2017.11.001 · DOI · Paper page
  137. Jo, 2000, NF-kappa B is required for H-ras oncogene induced abnormal cell proliferation and tumorigenesis, Oncogene, 19, 841, 10.1038/sj.onc.1203392 · DOI
  138. Lee, 2006, H-Ras selectively up-regulates MMP-9 and COX-2 through activation of ERK1/2 and NF-kappaB: an implication for invasive phenotype in rat liver epithelial cells, Int. J. Cancer, 119, 1767, 10.1002/ijc.22056 · DOI
  139. Sparmann, 2004, Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis, Cancer Cell, 6, 447, 10.1016/j.ccr.2004.09.028 · DOI · Paper page
  140. Meylan, 2009, Requirement for NF-kappaB signalling in a mouse model of lung adenocarcinoma, Nature, 462, 104, 10.1038/nature08462 · DOI · Paper page
  141. Jeay, 2003, Lysyl oxidase inhibits ras-mediated transformation by preventing activation of NF-kappa B, Mol. Cell. Biol., 23, 2251, 10.1128/MCB.23.7.2251-2263.2003 · DOI
  142. Kim, 2005, NF-kappaB inhibition radiosensitizes Ki-Ras-transformed cells to ionizing radiation, Carcinogenesis, 26, 1395, 10.1093/carcin/bgi081 · DOI
  143. Mizumoto, 2011, Activation of NF-kappaB is a novel target of KRAS-induced endometrial carcinogenesis, Clin. Cancer Res., 17, 1341, 10.1158/1078-0432.CCR-10-2291 · DOI
  144. Yu, 2014, Revisiting STAT3 signalling in cancer: new and unexpected biological functions, Nat. Rev. Cancer, 14, 736, 10.1038/nrc3818 · DOI · Paper page
  145. Huynh, 2017, The JAK/STAT3 axis: a comprehensive drug target for solid malignancies, Semin. Cancer Biol., 45, 13, 10.1016/j.semcancer.2017.06.001 · DOI · Paper page
  146. Shanmugam, 2016, Cancer prevention and therapy through the modulation of transcription factors by bioactive natural compounds, Semin. Cancer Biol., 40–41, 35, 10.1016/j.semcancer.2016.03.005 · DOI · Paper page
  147. Zushi, 1998, STAT3 mediates the survival signal in oncogenic ras-transfected intestinal epithelial cells, Int. J. Cancer, 78, 326, 10.1002/(SICI)1097-0215(19981029)78:3<326::AID-IJC12>3.0.CO;2-4 · doi:10.1002/(sici)1097-0215(19981029)78:3<326::aid-ijc12>3.0.co;2-4
  148. Garcia, 1997, Constitutive activation of Stat3 in fibroblasts transformed by diverse oncoproteins and in breast carcinoma cells, Cell Growth Differ., 8, 1267
  149. Plaza-Menacho, 2007, Ras/ERK1/2-mediated STAT3 Ser727 phosphorylation by familial medullary thyroid carcinoma-associated RET mutants induces full activation of STAT3 and is required for c-fos promoter activation, cell mitogenicity, and transformation, J. Biol. Chem., 282, 6415, 10.1074/jbc.M608952200 · DOI
  150. Tran, 2008, Combined Inactivation of MYC and K-Ras oncogenes reverses tumorigenesis in lung adenocarcinomas and lymphomas, PLoS One, 3, e2125, 10.1371/journal.pone.0002125 · DOI
  151. Yeh, 2009, Ha-ras oncogene-induced Stat3 phosphorylation enhances oncogenicity of the cell, DNA Cell Biol., 28, 131, 10.1089/dna.2008.0762 · DOI
  152. Gough, 2009, Mitochondrial STAT3 supports Ras-dependent oncogenic transformation, Science, 324, 1713, 10.1126/science.1171721 · DOI · Paper page
  153. Kim, 2009, Targeted disruption of stat3 reveals a major role for follicular stem cells in skin tumor initiation, Cancer Res., 69, 7587, 10.1158/0008-5472.CAN-09-1180 · DOI
  154. Fukuda, 2011, Stat3 and MMP7 contribute to pancreatic ductal adenocarcinoma initiation and progression, Cancer Cell, 19, 441, 10.1016/j.ccr.2011.03.002 · DOI · Paper page
  155. Mace, 2015, Single agent BMS-911543 Jak2 inhibitor has distinct inhibitory effects on STAT5 signaling in genetically engineered mice with pancreatic cancer, Oncotarget, 6, 44509, 10.18632/oncotarget.6332 · DOI
  156. Gough, 2014, STAT3 supports experimental K-RasG12D-induced murine myeloproliferative neoplasms dependent on serine phosphorylation, Blood, 124, 2252, 10.1182/blood-2013-02-484196 · DOI
  157. Yu, 2015, Mitochondrial STAT3 contributes to transformation of Barrett’s epithelial cells that express oncogenic Ras in a p53-independent fashion, Am. J. Physiol. Gastrointest. Liver Physiol., 309, G146, 10.1152/ajpgi.00462.2014 · DOI
  158. Saitoh, 2016, STAT3 integrates cooperative Ras and TGF-beta signals that induce Snail expression, Oncogene, 35, 1049, 10.1038/onc.2015.161 · DOI
  159. Yao, 2017, The FOXO 3-FOXM1 axis: a key cancer drug target and a modulator of cancer drug resistance, Semin. Cancer Biol.
  160. Koo, 1819, FOXM1: from cancer initiation to progression and treatment, Biochim. Biophys. Acta, 2012, 28
  161. Kalinichenko, 2015, Is there potential to target FOXM1 for ‘undruggable' lung cancers, Expert Opin. Ther. Targets, 19, 865, 10.1517/14728222.2015.1042366 · DOI
  162. Kopanja, 2015, Essential roles of FoxM1 in Ras-induced liver cancer progression and in cancer cells with stem cell features, J. Hepatol., 63, 429, 10.1016/j.jhep.2015.03.023 · DOI
  163. Park, 2009, FoxM1, a critical regulator of oxidative stress during oncogenesis, EMBO J., 28, 2908, 10.1038/emboj.2009.239 · DOI · Paper page
  164. Wang, 2014, Foxm1 transcription factor is required for the initiation of lung tumorigenesis by oncogenic Kras(G12D), Oncogene, 33, 5391, 10.1038/onc.2013.475 · DOI
  165. Eferl, 2003, AP-1: a double-edged sword in tumorigenesis, Nat. Rev. Cancer, 3, 859, 10.1038/nrc1209 · DOI · Paper page
  166. Mechta, 1997, Transformation by ras modifies AP1 composition and activity, Oncogene, 14, 837, 10.1038/sj.onc.1200900 · DOI · Paper page
  167. Zhang, 2017, Oncogenic RAS regulates long noncoding RNA orilnc1 in human cancer, Cancer Res., 77, 3745, 10.1158/0008-5472.CAN-16-1768 · DOI
  168. Cellurale, 2011, Requirement of c-Jun NH(2)-terminal kinase for Ras-initiated tumor formation, Mol. Cell. Biol., 31, 1565, 10.1128/MCB.01122-10 · DOI
  169. Yoshikawa, 2017, Ras inhibitors display an anti-metastatic effect by downregulation of lysyl oxidase through inhibition of the Ras-PI3K-Akt-HIF-1alpha pathway, Cancer Lett., 410, 82, 10.1016/j.canlet.2017.09.017 · DOI
  170. Lim, 2004, Ras-dependent induction of HIF-1alpha785 via the Raf/MEK/ERK pathway: a novel mechanism of Ras-mediated tumor promotion, Oncogene, 23, 9427, 10.1038/sj.onc.1208003 · DOI
  171. Zhang, 2017, Transcription factor Etv5 is essential for the maintenance of alveolar type II cells, Proc. Natl. Acad. Sci. U. S. A., 114, 3903, 10.1073/pnas.1621177114 · DOI
  172. Kar, 2013, Molecular mechanisms of ETS transcription factor-mediated tumorigenesis, Crit. Rev. Biochem. Mol. Biol., 48, 522, 10.3109/10409238.2013.838202 · DOI
  173. Zheng, 2013, Oncogene and non-oncogene addiction in inflammation-associated cancers, Future Oncol., 9, 561, 10.2217/fon.12.202 · DOI
  174. Borrello, 2008, Inflammation and cancer: the oncogene-driven connection, Cancer Lett., 267, 262, 10.1016/j.canlet.2008.03.060 · DOI
  175. Kitajima, 2016, Inflammation as a driver and vulnerability of KRAS mediated oncogenesis, Semin. Cell Dev. Biol., 58, 127, 10.1016/j.semcdb.2016.06.009 · DOI
  176. Ancrile, 2008, Oncogenic ras-induced expression of cytokines: a new target of anti-cancer therapeutics, Mol. Interv., 8, 22, 10.1124/mi.8.1.6 · DOI
  177. Leibovich-Rivkin, 2014, The inflammatory cytokine TNFalpha cooperates with Ras in elevating metastasis and turns WT-Ras to a tumor-promoting entity in MCF-7 cells, BMC Cancer., 14, 158, 10.1186/1471-2407-14-158 · DOI
  178. Munoz, 2016, Oncogenic Ras modulates p38 MAPK-mediated inflammatory cytokine production in glioblastoma cells, Cancer Biol. Ther., 17, 355, 10.1080/15384047.2016.1139249 · DOI
  179. Catanzaro, 2014, Oncogenic Ras induces inflammatory cytokine production by upregulating the squamous cell carcinoma antigens SerpinB3/B4, Nat. Commun., 5, 3729, 10.1038/ncomms4729 · DOI
  180. Giannou, 2017, NRAS destines tumor cells to the lungs, EMBO Mol. Med., 9, 672, 10.15252/emmm.201606978 · DOI
  181. Gstaiger, 2001, Skp2 is oncogenic and overexpressed in human cancers, Proc. Natl. Acad. Sci. U. S. A., 98, 5043, 10.1073/pnas.081474898 · DOI · Paper page
  182. Kulinski, 2017, Dysregulated expression of SKP2 and its role in hematological malignancies, Leuk. Lymphoma, 1
  183. Lee, 2015, Skp2-dependent ubiquitination and activation of LKB1 is essential for cancer cell survival under energy stress, Mol. Cell, 57, 1022, 10.1016/j.molcel.2015.01.015 · DOI
  184. Delogu, 2015, SKP2 cooperates with N-Ras or AKT to induce liver tumor development in mice, Oncotarget, 6, 2222, 10.18632/oncotarget.2945 · DOI
  185. Latres, 2001, Role of the F-box protein Skp2 in lymphomagenesis, Proc. Natl. Acad. Sci. U. S. A., 98, 2515, 10.1073/pnas.041475098 · DOI · Paper page
  186. Schepers, 2005, Oncogenic Ras blocks transforming growth factor-beta-induced cell-cycle arrest by degradation of p27 through a MEK/Erk/SKP2-dependent pathway, Exp. Hematol., 33, 747, 10.1016/j.exphem.2005.04.006 · DOI
  187. Batlle, 2017, Cancer stem cells revisited, Nat. Med., 23, 1124, 10.1038/nm.4409 · DOI · Paper page
  188. Siveen, 2017, Targeting acute myeloid leukemia stem cell signaling by natural products, Mol. Cancer, 16, 13, 10.1186/s12943-016-0571-x · DOI · Paper page
  189. Moon, 2014, Role of oncogenic K-Ras in cancer stem cell activation by aberrant Wnt/beta-catenin signaling, J. Natl. Cancer Inst., 106, djt373, 10.1093/jnci/djt373 · DOI · Paper page
  190. Gierut, 2015, Oncogenic K-Ras promotes proliferation in quiescent intestinal stem cells, Stem Cell Res., 15, 165, 10.1016/j.scr.2015.06.003 · DOI
  191. Liu, 2009, p21CIP1 attenuates Ras- and c-Myc-dependent breast tumor epithelial mesenchymal transition and cancer stem cell-like gene expression in vivo, Proc. Natl. Acad. Sci. U. S. A., 106, 19035, 10.1073/pnas.0910009106 · DOI · Paper page
  192. Xu, 2015, Let-7a regulates mammosphere formation capacity through Ras/NF-kappaB and Ras/MAPK/ERK pathway in breast cancer stem cells, Cell Cycle, 14, 1686, 10.1080/15384101.2015.1030547 · DOI
  193. Kim, 2010, Ras activation contributes to the maintenance and expansion of Sca-1pos cells in a mouse model of breast cancer, Cancer Lett., 287, 172, 10.1016/j.canlet.2009.06.010 · DOI
  194. Yoon, 2011, The small GTPase Rac1 is involved in the maintenance of stemness and malignancies in glioma stem-like cells, FEBS Lett., 585, 2331, 10.1016/j.febslet.2011.05.070 · DOI
  195. Quinlan, 2008, Activated Kras, but not Hras or Nras, may initiate tumors of endodermal origin via stem cell expansion, Mol. Cell. Biol., 28, 2659, 10.1128/MCB.01661-07 · DOI
  196. Yang, 2008, Phosphatidylinositol 3-kinase mediates bronchioalveolar stem cell expansion in mouse models of oncogenic K-ras-induced lung cancer, PLoS One, 3, e2220, 10.1371/journal.pone.0002220 · DOI
  197. Okada, 2014, Targeting the K-Ras–JNK axis eliminates cancer stem-like cells and prevents pancreatic tumor formation, Oncotarget, 5, 5100, 10.18632/oncotarget.2087 · DOI
  198. Maurelli, 2016, The role of oncogenic Ras in human skin tumorigenesis depends on the clonogenic potential of the founding keratinocytes, J. Cell Sci., 129, 1003, 10.1242/jcs.176842 · DOI
  199. Zhao, 2018, Oncogenic pathways that affect antitumor immune response and immune checkpoint blockade therapy, Pharmacol. Ther., 181, 76, 10.1016/j.pharmthera.2017.07.004 · DOI
  200. Weijzen, 1999, Modulation of the immune response and tumor growth by activated Ras, Leukemia, 13, 502, 10.1038/sj.leu.2401367 · DOI

200 of 204 shown

Cited by

Metadata

Authors
Khan, A. Q., Kuttikrishnan, S., Siveen, K. S., Prabhu, K. S., Shanmugakonar, M., Al- Naemi, H. A., Haris, M., Dermime, S., & Uddin, S.
Venue
Seminars in Cancer Biology
Publisher
Elsevier BV
Published
2019-02
Volume
54
Pages
1-13
ISSN
1044-579X (ISSN-L)
OpenAlex
W2793577044
Cited by
179
References
30
FWCI
5.26
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Funders
  • Medical Research Center (16354/16)
  • Hamad Medical Corporation, Doha, State of Qatar

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.